This is a regulatory disclosure made by Dr. Lal PathLabs Limited to the National Stock Exchange of India Limited and BSE Limited.
The disclosure intimates that a meeting of the Board of Directors is scheduled to be held on Friday, July 24, 2026. The primary agenda for the meeting is to consider and approve the unaudited financial results of the Company for the quarter ending June 30, 2026 (Q1 FY27). The results to be approved include both Standalone and Consolidated figures.
Furthermore, in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's own Code for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company will be closed. The closure period is from July 1, 2026, to July 26, 2026, with both dates inclusive.
The disclosure is made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The letter is signed by Vinay Gujral, Company Secretary & Compliance Officer, and is digitally dated June 29, 2026.